Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study
- PMID: 23542068
- DOI: 10.1053/j.gastro.2013.03.046
Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study
Abstract
Background & aims: Radiofrequency ablation (RFA), with or without endoscopic resection effectively eradicates Barrett's esophagus (BE) containing high-grade intraepithelial neoplasia and/or early-stage cancer. We followed patients who received RFA for BE containing high-grade intraepithelial neoplasia and/or early-stage cancer for 5 years to determine the durability of treatment response.
Methods: We followed 54 patients with BE (2-12 cm), previously enrolled in 4 consecutive cohort studies in which they underwent focal endoscopic resection in case of visible lesions (n = 40 [72%]), followed by serial RFA every 3 months. Patients underwent high-resolution endoscopy with narrow-band imaging at 6 and 12 months after treatment and then annually for 5 years (median, 61 months; interquartile range, 53-65 months); random biopsy samples were collected from neosquamous epithelium and gastric cardia. After 5 years, endoscopic ultrasound and endoscopic resection of neosquamous epithelium were performed. Outcomes included sustained complete remission of neoplasia or intestinal metaplasia (IM), IM in gastric cardia, or buried glands in neosquamous epithelium.
Results: After 5 years, Kaplan-Meier analysis showed sustained complete remission of neoplasia and intestinal metaplasia in 90% of patients; neoplasia recurred in 3 patients and was managed endoscopically. Focal IM in the cardia was found in 19 of 54 patients (35%), in 53 of 1143 gastric cardia biopsies (4.6%). The incidence of IM of the cardia did not increase over time; and IM was diagnosed based on only a single biopsy in 89% of patients. Buried glands were detected in 3 of 3543 neosquamous epithelium biopsies (0.08%, from 3 patients). No endoscopic resection samples had buried glands.
Conclusions: Among patients who have undergone RFA with or without endoscopic resection for neoplastic BE, 90% remain in remission at 5-year follow-up, with all recurrences managed endoscopically. This treatment approach is therefore an effective and durable alternative to esophagectomy; www.trialregister.nl number, NTR2938.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
Can You Stop Surveillance After Radiofrequency Ablation of Barrett's Esophagus? A Glass Half Full.Gastroenterology. 2013 Jul;145(1):39-42. doi: 10.1053/j.gastro.2013.05.039. Epub 2013 May 29. Gastroenterology. 2013. PMID: 23727498 No abstract available.
Similar articles
-
Radiofrequency ablation and endoscopic resection in a single session for Barrett's esophagus containing early neoplasia: a feasibility study.Endoscopy. 2012 Dec;44(12):1096-104. doi: 10.1055/s-0032-1325731. Epub 2012 Oct 29. Endoscopy. 2012. PMID: 23108809
-
Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia.Clin Gastroenterol Hepatol. 2010 Jan;8(1):23-9. doi: 10.1016/j.cgh.2009.07.003. Epub 2009 Aug 11. Clin Gastroenterol Hepatol. 2010. PMID: 19602454 Clinical Trial.
-
Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II).Gut. 2016 Apr;65(4):555-62. doi: 10.1136/gutjnl-2015-309298. Epub 2015 Mar 2. Gut. 2016. PMID: 25731874
-
AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.Gastroenterology. 2020 Feb;158(3):760-769. doi: 10.1053/j.gastro.2019.09.051. Epub 2019 Nov 12. Gastroenterology. 2020. PMID: 31730766 Review.
-
Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.Gastroenterology. 2016 Nov;151(5):822-835. doi: 10.1053/j.gastro.2016.09.040. Epub 2016 Oct 1. Gastroenterology. 2016. PMID: 27702561 Review.
Cited by
-
Endoscopic Resection and Radiofrequency Ablation for Early Esophageal Neoplasia.Dig Dis. 2016;34(5):469-75. doi: 10.1159/000445221. Epub 2016 Jun 22. Dig Dis. 2016. PMID: 27333327 Free PMC article. Review.
-
Useful strategies to prevent severe stricture after endoscopic submucosal dissection for superficial esophageal neoplasm.World J Gastroenterol. 2015 Jun 21;21(23):7120-33. doi: 10.3748/wjg.v21.i23.7120. World J Gastroenterol. 2015. PMID: 26109798 Free PMC article. Review.
-
Recurrent intestinal metaplasia at the gastroesophageal junction following endoscopic eradication of dysplastic Barrett's esophagus may not be benign.Endosc Int Open. 2016 Aug;4(8):E849-58. doi: 10.1055/s-0042-109608. Epub 2016 Aug 9. Endosc Int Open. 2016. PMID: 27540572 Free PMC article.
-
Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease.Surg Endosc. 2016 Sep;30(9):4102-13. doi: 10.1007/s00464-016-5071-y. Epub 2016 Jun 29. Surg Endosc. 2016. PMID: 27357927
-
Quality indicators for Barrett's endotherapy (QBET): UK consensus statements for patients undergoing endoscopic therapy for Barrett's neoplasia.Frontline Gastroenterol. 2019 Aug 14;11(4):259-271. doi: 10.1136/flgastro-2019-101247. eCollection 2020. Frontline Gastroenterol. 2019. PMID: 32587669 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical